Inhaled study drug for virus infections on ventilators
Part of Infections, Lungs & breathing clinical trials.
This study tests an inhaled study drug (SNG001) for adults on a breathing machine in the ICU due to a viral lung infection. The goal is to see if the drug can help patients recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are on a breathing machine in the ICU because of a virus infection (like flu, RSV, COVID-19).
- You are 50 years or older, or you are between 18 and 49 and have a weakened immune system.
- Treatment must start within 48 hours of being placed on the breathing machine.
- You must not have had a lung transplant, severe liver failure, or certain severe heart conditions.
- You must not be pregnant, breastfeeding, or have certain types of cancer or immune-suppressing treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an experimental drug called AP1189, added to standard hospital care, can help people hospitalized with severe breathing problems from viruses like COVID-19, flu, or RSV. The goal is to see if it reduces the need for mechanical ventilation or other life support.
This Phase 2 trial tests an investigational medicine (given in increasing doses) for hospitalized people with pneumonia who need supplemental oxygen. It aims to see if the medicine is safe and potentially helps the pneumonia process in the early hospital period.
This trial studies whether giving antibiotics affects recovery in adults hospitalized with moderately severe infections caused by specific viruses (influenza, parainfluenza, RSV, or hMPV). It may help show when antibiotics are helpful or unnecessary for viral airway illness.
This Phase 2 trial tests Rhu-pGSN in adults with acute respiratory distress syndrome (ARDS) caused by an infection. If you qualify, the study may help determine whether the drug improves outcomes in this short-term, life-threatening lung condition.
This trial tests whether INNA-051 can help prevent respiratory infections caused by viruses in healthy adults aged 18 to 45. It may be an option if you are at higher risk of catching such infections due to your living or work situation.
This early (Phase 1) study tests AVM0703 in adults who are very sick with lung failure caused by COVID-19 or influenza (flu). It aims to see if the treatment is safe and potentially helpful when standard rescue breathing treatments are not enough.
Hear when a new Viral Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.